DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
32.81B
Market cap32.81B
Price-Earnings ratio
33.69
Price-Earnings ratio33.69
Dividend yield
—
Dividend yield—
Average volume
3.38M
Average volume3.38M
High today
$87.12
High today$87.12
Low today
$84.75
Low today$84.75
Open price
$84.75
Open price$84.75
Volume
3.07M
Volume3.07M
52 Week high
$92.59
52 Week high$92.59
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $86.90. The company's market cap stands at 32.81B, with a P/E ratio of 33.69.

On 2026-10-05, DexCom(DXCM) stock traded between a low of $84.75 and a high of $87.12. Shares are currently priced at $86.90, which is +2.5% above the low and -0.3% below the high.

DexCom(DXCM) shares are trading with a volume of 3.07M, against a daily average of 3.38M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

DXCM News

Zacks 3d
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research

...

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
TipRanks 4d
DexCom price target raised to $105 from $90 at RBC Capital

RBC Capital raised the firm’s price target on DexCom (DXCM) to $105 from $90 and keeps an Outperform rating on the shares as part of a broader research note pre...

Simply Wall St 6d
How Could DexCom Turn Type 2 CGM Gaps Into Growth?

DexCom (NasdaqGS:DXCM) released its global "State of Type 2 Report" at EASD 2026, focusing on Type 2 diabetes care and CGM use. The report highlights gaps in a...

How Could DexCom Turn Type 2 CGM Gaps Into Growth?

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
16.1%
Sell
0%

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.